STOCK TITAN

Electromed - ELMD STOCK NEWS

Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.

Electromed Inc. (ELMD) specializes in advanced airway clearance solutions through its clinically validated SmartVest system. This dedicated news hub provides investors and healthcare stakeholders with essential updates on respiratory care innovations, regulatory compliance, and corporate developments.

Find authoritative coverage of ELMD's progress in HFCWO technology, including product enhancements, partnership announcements, and quality certifications. Our curated news selection emphasizes factual reporting on clinical trial outcomes and market expansion initiatives within the medical device sector.

Regular updates include earnings disclosures, manufacturing quality milestones, and research collaborations. Bookmark this resource for streamlined access to verified ELMD developments that impact respiratory therapy standards and investment considerations.

Rhea-AI Summary

Electromed (NYSE American: ELMD) has announced its participation in the 15th Annual LD Micro Invitational, scheduled for April 9-10, 2025, at the Westin Grand Central in New York. Jim Cunniff, President and CEO, will present on April 10 at 2:30 PM ET.

The event will showcase 50+ companies and features:

  • Registration starting April 9 at 2:00 PM ET
  • Keynote presentations
  • CBIZ Offices Rooftop happy hour
  • Company presentations beginning April 10 at 8:00 AM ET
  • LD Micro Moneyball Afterparty at the Knickerbocker Hotel

Interested investors can access the live webcast of the presentation through the event registration link: https://ldinv15.sequireevents.com/

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
conferences
-
Rhea-AI Summary

Electromed (NYSE American: ELMD) announced that its board of directors has authorized a new share repurchase program of up to $5.0 million of common stock on March 6, 2025. The company, which specializes in innovative airway clearance technologies, will execute the buyback through various means including open market purchases, private transactions, and block trades, depending on market conditions.

Management will determine the timing and volume of repurchases based on market conditions and other factors. The board will periodically review and may modify the authorization's terms and size. CEO Jim Cunniff stated that this initiative demonstrates confidence in their business strength and commitment to creating shareholder value while maintaining financial flexibility for future growth investments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
buybacks
-
Rhea-AI Summary

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its participation in two upcoming investor conferences.

The company will present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference on Tuesday, March 18, 2025, at 10:30 a.m. Eastern Time. Additionally, management will present at the Sidoti Virtual Small-Cap Conference on Thursday, March 20, 2025, at 1:45 p.m. Eastern Time.

Live and archived webcasts for both events will be accessible through the Electromed website under Events & Presentations. For the Oppenheimer conference, investors can request meetings through their Oppenheimer representative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
conferences
Rhea-AI Summary

Electromed (NYSE American: ELMD) reported record financial results for Q2 FY 2025. Net revenue increased 18.7% to $16.3 million, while operating income reached $2.5 million (15.6% of net revenues). Net income grew to $2.0 million ($0.22 per diluted share), up from $1.7 million ($0.19 per diluted share) in Q2 FY 2024.

The company's direct homecare business saw a 15.2% increase to $14.6 million, driven by increased referrals and approvals. The field sales force expanded to 60 employees, with 54 direct sales representatives. Gross profit improved to 77.7% of net revenues ($12.6 million). As of December 31, 2024, Electromed maintained a strong financial position with $16.2 million in cash, $22.8 million in accounts receivable, and no debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.97%
Tags
-
Rhea-AI Summary

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced it will release its fiscal 2025 second quarter financial results on February 11, 2025, after market close. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results.

Investors can join the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). A live webcast will be available in the Investor Relations section of Electromed's website. For those unable to attend, a replay will be accessible via phone using replay pin 10196088 or through the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
conferences earnings
-
Rhea-AI Summary

Electromed, a leader in airway clearance technologies, announced its fiscal Q1 2025 financial results. Net revenue rose by 19.0% to $14.7 million, with gross margin improving to 78.3%. Operating income increased to $1.9 million, and net income surged to $1.5 million, or $0.16 per diluted share. The company repurchased 262,756 shares at an average price of $17.26, totaling approximately $4.5 million. Electromed continues to invest in growth initiatives, including the expansion of its direct sales force to 53 reps and the launch of a new marketing campaign. Cash balance decreased by $2.2 million, primarily due to share repurchases, leaving $13.9 million in cash and no debt. The company achieved a working capital of $33.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
Rhea-AI Summary

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced it will release its fiscal 2025 first quarter financial results on November 12, 2024, after market close. Management will host a conference call at 5:00 p.m. Eastern Time to discuss the results. Investors can join via phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International), or watch the webcast through the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences earnings
-
Rhea-AI Summary

Electromed (NYSE American: ELMD) has appointed Peter Horwich as Vice President, Marketing. Horwich brings over 20 years of experience in Medical Technology marketing, previously serving at Abiomed (now J&J MedTech) where he directed Global Strategic Marketing for Respiratory Therapies. His experience includes roles at Medtronic, Arizant, Entegris, and Guidant. CEO Jim Cunniff highlighted that this strategic appointment comes during a period of business growth and aims to drive therapy adoption for SmartVest Clearway to support revenue growth goals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
management
-
Rhea-AI Summary

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced a new $5.0 million share repurchase authorization effective September 11, 2024. This follows the completion of their previous repurchase program in Q4 fiscal 2024. The company's board will determine the timing and amount of repurchases based on market conditions. Repurchases may be made through various means, including open market transactions and block trades.

CEO Jim Cunniff stated that this decision follows Electromed's record performance in fiscal 2024 and reflects the board's confidence in future growth. The company's strong revenue growth and profitability are generating robust free cash flow, allowing for shareholder value creation while continuing business investments. Management believes the stock is undervalued given their strong financial results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
buybacks
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) reported record financial results for Q4 and FY 2024. Highlights include:

- Q4 net revenues increased 9.0% to $14.8 million
- Q4 operating income up 56.3% to $2.3 million
- Q4 net income reached $1.8 million or $0.20 per diluted share
- FY 2024 net revenue grew 13.8% to $54.7 million
- FY 2024 operating income increased 64.2% to $6.6 million
- FY 2024 net income totaled $5.2 million or $0.58 per diluted share

The company attributed growth to investments in commercial infrastructure and market development initiatives. As of June 30, 2024, Electromed had $16.1 million in cash, $23.3 million in accounts receivable, and no debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
Electromed

NYSE:ELMD

ELMD Rankings

ELMD Stock Data

195.01M
6.82M
20.54%
43.56%
2.44%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
NEW PRAGUE